- Shares of Kadmon Holdings (KDMN +72.9%) have skyrocketed following this morning's announcement the company would be acquired by Sanofi (SNY -2.7%) for ~$1.9B.
- The acquisition gives Sanofi Rezurock (belumosudil), a recently approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.
- Rezurock is also in phase 2 for systemic sclerosis.
- In phase 1, Kadmon has KD033, an anti-PD-L1/IL-15 fusion protein for solid tumors.